MedTrace Logo

Trial of Pemetrexed With or Without PF-3512676 in Advanced Non-Small Cell Lung Cancer

NCT00321308 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2009-09-28

No results posted yet for this study

Summary

To assess the efficacy and safety of PF-3512676 administered in combination with pemetrexed for the treatment of patients with locally advanced or metastatic NSCLC who have failed one prior chemotherapy regimen

Conditions

  • Carcinoma, Non-Small Cell Lung

Interventions

DRUG

pemetrexed

500 mg/m2 intravenously Day 1 of each 21 day cycle until disease progression or unacceptable toxicity

DRUG

pemetrexed + PF-3512676

pemetrexed 500 mg/m2 intravenously Day 1 of each 21 day cycle until disease progression or unacceptable toxicity

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2008-01-31
Completion
2008-01-31

Countries

  • United States
  • Germany
  • Italy

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00321308 on ClinicalTrials.gov